Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 6451 - 6475 of 8039 in total
Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Investigational
Matched Description: … Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity …
PM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.
Investigational
Matched Description: … PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types …
Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.
Investigational
Matched Description: … Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from …
RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.
Investigational
Matched Description: … tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of
Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
Investigational
Matched Description: … IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of
Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.
Vet approved
Matched Description: … the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of
Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
Investigational
Matched Description: … Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous …
Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid Tumors, Advanced BRAF-mutant Cancers, and Non Small Cell Lung Cancer (NSCLC), among others.
Investigational
Matched Description: … Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid …
CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma).
Investigational
Matched Description: … CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With …
Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B).
Investigational
Matched Description: … Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational …
PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus).
Investigational
Matched Description: … investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of
Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).
Investigational
Matched Description: … Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy …
2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).
Investigational
Matched Description: … 2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of
Dirocaftor is under investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis).
Investigational
Matched Description: … investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of
G305 is a recombinant NY-ESO-1 protein plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with LV305.
Investigational
Matched Description: … G305 is an active component of CMB305 along with [LV305].[L47346] …
AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
Investigational
Matched Description: … It is under investigation for the treatment of collagen Q congenital myasthenia. …
A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]
Experimental
Matched Description: … A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH ( …
An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)
Experimental
Matched Description: … Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. …
An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)
Experimental
Matched Description: … An N-acyl derivative of neuraminic acid. …
An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)
Experimental
Matched Description: … An N-acyl derivative of neuraminic acid. …
Bafetinib has been used in trials studying the treatment of Adult Gliosarcoma, Adult Mixed Glioma, Adult Glioblastoma, Chronic Myeloid Leukemia, and Acute Lymphocytic Leukemia, among others.
Investigational
Matched Description: … Bafetinib has been used in trials studying the treatment of Adult Gliosarcoma, Adult Mixed Glioma, Adult …
Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.
Investigational
Matched Description: … Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food …
Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).
Investigational
Matched Description: … Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL …
Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
Investigational
Matched Description: … Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, …
Poly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).
Investigational
Matched Description: … investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of
Displaying drugs 6451 - 6475 of 8039 in total